You Searched For "zymergen" and got 15 results
Sort By:
1 min read
Zymergen rebounds with a 85% rally after Cathie Wood's Ark Invest tripled its stake in the synthetic biology company
The Ark Genomic Revolution ETF bought more than 2.5 million shares of the company on Wednesday, bri…
Matthew Fox  Â
1 min read
A recent IPO bought by Cathie Wood's Ark Invest just tanked 77% after it said product 'issues' will lead to little revenue this year and next
The Ark Genomic Revolution ETF owned just over 1 million shares of Zymergen, leading to a loss of m…
Matthew Fox  Â
2 mins read
Cathie Wood's Ark Invest just doubled a multi-million-share position in a SPAC merging with Ginkgo Bioworks
Ark Invest first began purchasing shares of the Ginkgo Bioworks SPAC on August 3 and now owns 14.5 …
Matthew Fox  Â
2 mins read
Ginkgo Bioworks plunges 24% after short-seller calls it a 'Frankenstein mash-up of the worst frauds'
The decline in Ginkgo hurts investors like Ark Invest, which owned a combined $325 million stake in…
Matthew Fox  Â
2 mins read
Cathie Wood's favorite type of stocks still face significant challenges in staging a recovery, Goldman Sachs says
"Some unprofitable growth companies will need to raise capital externally in order to remain solven…
Matthew Fox  Â
1 min read
Ark Invest's flagship fund has dumped nearly all of its 7 million shares of Zillow since the online real estate firm shuttered its home-flipping business
"When there is a fundamental change in the story, like Zillow's decision to abandon iBuying, that v…
Matthew Fox  Â
2 mins read
Here are Insider's biggest healthcare stories for November
These are Insider's biggest healthcare stories for the month of November.
Leah Rosenbaum  Â
2 mins read
What's ahead for COVID-19 treatments after Pfizer says its antiviral pill works
These are Insider's biggest healthcare stories for the week ending November 5.
Leah Rosenbaum  Â
2 mins read
Cathie Wood's funds bought the dip in Gingko Bioworks after a short-seller called it a 'Frankenstein' of frauds
Ark jumped in as Gingko's stock slid after short-seller Scorpion Capital published a report bashing…
Shalini Nagarajan  Â
4 mins read
A Silicon Valley startup with 20 patents under its belt just raised $400 million from SoftBank and Goldman Sachs to make materials from living things
Aside from Zymergen, a handful of other synthetic biology startups have attracted fresh funding in …
Erin Brodwin  Â
1 min read
What's next for Walgreens
These are Business Insider's biggest healthcare stories for January 28.
Lydia Ramsey Pflanzer  Â
6 mins read
After a kick-start from Bill Gates, a Silicon Valley company aims to be the 'Intel Inside' of the $200 billion sweetener and skincare market
In its Biossance products, the key ingredient that Amyris makes is called squalene. Normally derive…
Erin Brodwin  Â
2 mins read
A startup that's bringing together 'two disparate but unstoppable trends' just raised $400 million from investors led by SoftBank
On Thursday, Relay Therapeutics said it had raised $400 million in a series C round led by SoftBank…
Lydia Ramsey  Â
4 mins read
Dispensed: A secret patch, a $31 million pay package, and Amazon's ambitions in a $300 billion healthcare-technology market
And a quick Friday update on the urgent care front: Last week, I took a look at the industry overal…
Lydia Ramsey  Â
18 mins read
uBiome convinced Silicon Valley that testing poop was worth $600 million. Then the FBI came knocking. Here's the inside story.
[T]he Board and management team have taken strong and swift action to address the issues that have …